Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
February 09, 2024 06:00 ET
|
Adagene Inc.
- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference - - Initiated evaluation...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
January 16, 2024 17:01 ET
|
Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
January 04, 2024 05:00 ET
|
Adagene Inc.
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime...
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
November 03, 2023 12:00 ET
|
Adagene Inc.
- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated...
天演药业将在第38届SITC年会上以海报形式公布其精准掩蔽型抗CTLA-4安全抗体SAFEbody® ADG126剂量优化试验结果
October 12, 2023 08:00 ET
|
Adagene Inc.
-数据将展示ADG126的作用机制及与帕博利珠单抗联用连续给药的剂量优化，10 mg/kg每3周一次的方案目前正在微卫星稳定型晚期结直肠癌中进行队列扩展研究 中国苏州和美国圣地亚哥, Oct. 12, 2023 (GLOBE NEWSWIRE) --...
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 12, 2023 08:00 ET
|
Adagene Inc.
- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort – SAN DIEGO and SUZHOU, China, Oct....
Adagene to Present at Investor and Scientific Conferences in September
September 07, 2023 06:00 ET
|
Adagene Inc.
– Adagene’s CEO, Dr. Peter Luo, participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies – SAN DIEGO and SUZHOU, China, Sept. 07, 2023 ...
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
August 31, 2023 07:32 ET
|
Adagene Inc.
- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – -...
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
May 04, 2023 09:00 ET
|
Adagene Inc.
SAN DIEGO and SUZHOU, China, May 04, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...
Adagene Announces Updates to its Board of Directors
April 28, 2023 07:00 ET
|
Adagene Inc.
SAN DIEGO and SUZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...